Nicholas George Klicos

Array ( [id] => 20256136 [patent_doc_number] => 12428479 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-09-30 [patent_title] => CLDN18.2-targeting antibody, bispecific antibody and use thereof [patent_app_type] => utility [patent_app_number] => 17/818072 [patent_app_country] => US [patent_app_date] => 2022-08-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 38 [patent_figures_cnt] => 15 [patent_no_of_words] => 22925 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 62 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17818072 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18436084 [patent_doc_number] => 20230183378 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-15 [patent_title] => MULTIMERS, TETRAMERS & OCTAMERS [patent_app_type] => utility [patent_app_number] => 17/817912 [patent_app_country] => US [patent_app_date] => 2022-08-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31932 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17817912 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18748389 [patent_doc_number] => 11807685 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-11-07 [patent_title] => Anti-CD47 antibody and uses thereof [patent_app_type] => utility [patent_app_number] => 17/817448 [patent_app_country] => US [patent_app_date] => 2022-08-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 19 [patent_no_of_words] => 19002 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 135 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17817448 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18192709 [patent_doc_number] => 20230046228 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-16 [patent_title] => METHODS FOR MANUFACTURING GENETICALLY ENGINEERED CAR-T CELLS [patent_app_type] => utility [patent_app_number] => 17/814930 [patent_app_country] => US [patent_app_date] => 2022-07-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34304 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -31 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17814930 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18125188 [patent_doc_number] => 20230010803 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-01-12 [patent_title] => TREATMENTS FOR DIFFUSE LARGE B-CELL LYMPHOMA [patent_app_type] => utility [patent_app_number] => 17/854211 [patent_app_country] => US [patent_app_date] => 2022-06-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5956 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 59 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17854211 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17774979 [patent_doc_number] => 20220241328 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-04 [patent_title] => USE OF CD8-TARGETED VIRAL VECTORS [patent_app_type] => utility [patent_app_number] => 17/572611 [patent_app_country] => US [patent_app_date] => 2022-01-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 87406 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -34 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17572611 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17685941 [patent_doc_number] => 20220193233 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-23 [patent_title] => STABILIZED ARTIFICIAL IMMUNE COMPLEX ACTIVE IMMUNIZATION STRATEGY THAT SUPPORTS B CELL AND DENDRITIC CELL PROGRAMMING FOR CANCER IMMUNOTHERAPY [patent_app_type] => utility [patent_app_number] => 17/541273 [patent_app_country] => US [patent_app_date] => 2021-12-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6205 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17541273 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18830878 [patent_doc_number] => 20230399403 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-14 [patent_title] => MONOCLONAL ANTIBODIES DIRECTED AGAINST PROGRAMMED DEATH-1 PROTEIN AND THEIR USE IN MEDICINE [patent_app_type] => utility [patent_app_number] => 18/035172 [patent_app_country] => US [patent_app_date] => 2021-11-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 56776 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -101 [patent_words_short_claim] => 59 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18035172 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19081920 [patent_doc_number] => 20240108721 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-04 [patent_title] => DUAL TARGETING CHIMERIC ANTIGEN RECEPTORS [patent_app_type] => utility [patent_app_number] => 18/034669 [patent_app_country] => US [patent_app_date] => 2021-10-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27612 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18034669 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18902769 [patent_doc_number] => 20240018254 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-18 [patent_title] => ANTI-CD73 ANTIBODY AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/250010 [patent_app_country] => US [patent_app_date] => 2021-10-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9336 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18250010 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18902769 [patent_doc_number] => 20240018254 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-18 [patent_title] => ANTI-CD73 ANTIBODY AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/250010 [patent_app_country] => US [patent_app_date] => 2021-10-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9336 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18250010 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17548149 [patent_doc_number] => 20220119490 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-21 [patent_title] => MODULATORS OF CELL SURFACE PROTEIN INTERACTIONS AND METHODS AND COMPOSITIONS RELATED TO SAME [patent_app_type] => utility [patent_app_number] => 17/489598 [patent_app_country] => US [patent_app_date] => 2021-09-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 70392 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -31 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17489598 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18725839 [patent_doc_number] => 20230340064 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-26 [patent_title] => MAGE-A3 SPECIFIC T CELL RECEPTORS AND THEIR USE [patent_app_type] => utility [patent_app_number] => 18/028002 [patent_app_country] => US [patent_app_date] => 2021-09-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15349 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 9 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18028002 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18725839 [patent_doc_number] => 20230340064 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-26 [patent_title] => MAGE-A3 SPECIFIC T CELL RECEPTORS AND THEIR USE [patent_app_type] => utility [patent_app_number] => 18/028002 [patent_app_country] => US [patent_app_date] => 2021-09-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15349 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 9 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18028002 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19707894 [patent_doc_number] => 20250018036 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-01-16 [patent_title] => IMMUNOTHERAPY TARGETING SOX2 ANTIGENS [patent_app_type] => utility [patent_app_number] => 18/246502 [patent_app_country] => US [patent_app_date] => 2021-09-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 43795 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18246502 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17312907 [patent_doc_number] => 20210401955 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-30 [patent_title] => CD4 T cells provide antibody access to immunoprivileged tissue [patent_app_type] => utility [patent_app_number] => 17/467574 [patent_app_country] => US [patent_app_date] => 2021-09-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18282 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 39 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17467574 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17387038 [patent_doc_number] => 20220034890 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-03 [patent_title] => USE OF BMMF1 REP PROTEIN AS A BIOMARKER FOR BREAST CANCER [patent_app_type] => utility [patent_app_number] => 17/444778 [patent_app_country] => US [patent_app_date] => 2021-08-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6543 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17444778 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17387038 [patent_doc_number] => 20220034890 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-03 [patent_title] => USE OF BMMF1 REP PROTEIN AS A BIOMARKER FOR BREAST CANCER [patent_app_type] => utility [patent_app_number] => 17/444778 [patent_app_country] => US [patent_app_date] => 2021-08-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6543 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17444778 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17387038 [patent_doc_number] => 20220034890 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-03 [patent_title] => USE OF BMMF1 REP PROTEIN AS A BIOMARKER FOR BREAST CANCER [patent_app_type] => utility [patent_app_number] => 17/444778 [patent_app_country] => US [patent_app_date] => 2021-08-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6543 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17444778 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19417332 [patent_doc_number] => 20240293455 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-05 [patent_title] => ARMED NK CELLS FOR UNIVERSAL CELL THERAPY [patent_app_type] => utility [patent_app_number] => 18/018687 [patent_app_country] => US [patent_app_date] => 2021-08-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31526 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18018687 [rel_patent_id] =>[rel_patent_doc_number] =>)